Helius Medical Technologies Shares Positive Findings on PoNS Therapy
Positive Outcomes from PoNSTEP Study Unveiled
During a recent gathering of global specialists at the Consortium of Multiple Sclerosis Centers Annual Meeting, Helius Medical Technologies, Inc. (NASDAQ: HSDT) revealed compelling findings from the PoNS Therapeutic Experience Program (PoNSTEP). This innovative research, led by Deborah Backus, PT, Ph.D., Vice President of Research and Innovation at Atlanta’s Shepard Center, showcased the long-term benefits of PoNS Therapy for individuals with multiple sclerosis (MS).
Highlighting the Importance of Treatment Adherence
At the meeting, Dr. Backus emphasized how crucial treatment adherence emerged as a key factor for achieving significant improvement in gait disabilities over the 14-week therapy. Notably, the benefits of this targeted therapy persisted even six months post-treatment, affirming its sustained therapeutic effects. The PoNSTEP study corroborates previously reported data on the long-term advantages of PoNS Therapy, particularly for patients who face balance deficits due to traumatic brain injuries.
Engagement with Healthcare Professionals
Dr. Antonella Favit-Van Pelt, Chief Medical Officer at Helius, reflected on the enthusiastic reception of the study results by healthcare professionals from both the U.S. and Canada. She expressed excitement about sharing the clinical trial evidence that demonstrates PoNS Therapy's long-lasting therapeutic benefits for rehabilitation among MS patients. Favit-Van Pelt noted the therapy's unique capacity to act directly on the central nervous system, which differentiates it from traditional peripheral neuromuscular interventions.
Positive Developments in Reimbursement
Attendees at the Consortium were encouraged by Helius' recent achievements in securing initial reimbursement on both federal and private levels, showcasing the company's dedication to expanding access to PoNS Therapy for MS patients. The proactive communication with health insurance providers was seen as vital in ensuring that more people can benefit from this innovative treatment.
Improving Access to Essential Therapy
Dane Andreeff, President and CEO of Helius, shared his anticipation regarding increasing reimbursement coverage for PoNS Therapy. He believes this will significantly reduce barriers for healthcare providers when prescribing PoNS, ultimately enhancing patient access to a therapy that has proven itself valuable.
Understanding the PoNSTEP Study
The PoNS Therapeutic Experience Program (PoNSTEP) stands as a pioneering study aimed at assessing the real-world impacts of PoNS Therapy on gait deficits within the MS community. Conducted in various centers of excellence across the nation, the study tracked the adherence of participants to PoNS Therapy, which encompasses the use of the PoNS device integrated with supervised physical therapy.
Mechanism of PoNS Therapy Unpacked
The Portable Neuromodulation Stimulator, or PoNS, represents an innovative approach to therapy that applies neurostimulation using a mouthpiece. By delivering mild electrical impulses to the tongue, this non-invasive, orally applied treatment is designed to work alongside physical rehabilitation exercises aimed at enhancing gait and balance.
Effectiveness in Various Conditions
Beyond its application for MS, the PoNS device has demonstrated effectiveness in addressing gait and balance challenges stemming from other neurological injuries, including stroke and traumatic brain injuries. In Canada, where PoNS has received authorization for multiple uses, the therapy has proven beneficial in reducing the risk of falls among patients. PoNS is also gaining traction in Australia, where it is available as a supportive treatment for balance and gait improvement.
About Helius Medical Technologies, Inc.
Helius Medical Technologies continues to make strides in neurotechnology, focusing on devices that harness the brain's natural ability to facilitate recovery and promote neuroplasticity. The company’s commitment to patient wellness is reflected in its first commercial product, the Portable Neuromodulation Stimulator. To explore more about PoNS and Helius Medical Technologies, you can visit their official site.
Frequently Asked Questions
What are the main findings of the PoNSTEP study?
The PoNSTEP study highlighted significant long-term benefits of PoNS Therapy in improving gait deficits in patients with multiple sclerosis, emphasizing the importance of treatment adherence.
How does PoNS Therapy work?
PoNS Therapy involves the use of a Portable Neuromodulation Stimulator that delivers neurostimulation through a mouthpiece, combined with physical rehabilitation to enhance balance and gait.
Who participated in the PoNSTEP study?
Forty-three participants with multiple sclerosis and gait deficits were recruited for the PoNSTEP study conducted at six Centers of Excellence across the United States.
What is the expected impact of the increased reimbursement coverage?
Increased reimbursement coverage is anticipated to lower barriers for healthcare providers to prescribe PoNS Therapy, ultimately improving access for patients.
Where can I find more information about PoNS Therapy?
For further details on PoNS Therapy and its applications, you can visit the Helius Medical Technologies website for comprehensive resources.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
